Smoldering multiple myeloma (SMM)

طلب موعد

Stages

Smoldering multiple myeloma does not use numbered stages such as stage 1, stage 2 or stage 3. Instead, it is classified by the risk of progression.

If a myeloma-defining event occurs, the diagnosis changes to active multiple myeloma. The care team then stages the active myeloma and creates a treatment plan.

طلب تحديد موعد
التشخيص والعلاجSurvival rates
15/08/2026

Living with smoldering multiple myeloma (SMM)?

Connect with others like you for support and answers to your questions in the Blood Cancers & Disorders support group on Mayo Clinic Connect, a patient community.

Blood Cancers & Disorders Discussions

shenriq
Essential Thrombocythemia: Looking for information and support

709 Replies Sat, Sep 05, 2026

Lori, Volunteer Mentor
My Bone Marrow Transplant (BMT/SCT) story: Will you share yours?

921 Replies Wed, Sep 02, 2026

hikerny
Anyone have chronic lymphocytic leukemia (CLL)?

376 Replies Wed, Sep 02, 2026

See more discussions
  1. Multiple myeloma. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf. Accessed August 4, 2026.
  2. Kumar SK, et al. Multiple myeloma, version 5.2026, NCCN Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2026; doi:10.6004/jnccn.2026.0001.
  3. Zanwar S, et al. Diagnosis, risk stratification and management of smouldering multiple myeloma. Nature Reviews Clinical Oncology. 2026; doi:10.1038/s41571-026-01119-0.
  4. Mateos MV, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer Journal. 2020; doi:10.1038/s41408-020-00366-3.
  5. Chabrun F, et al. Enhanced dynamic risk stratification of smoldering multiple myeloma. Nature Medicine. 2026; doi:10.1038/s41591-026-04304-x.
  6. Ludwig H, et al. Temporal trends in progression risk in smoldering myeloma: A systematic review. eClinicalMedicine. 2026; doi:10.1016/j.eclinm.2025.103750.
  7. Sandecka V, et al. Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies. Blood Cancer Journal. 2023; doi:10.1038/s41408-023-00906-7.
  8. Ntanasis-Stathopoulos I, et al. Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies. Blood Cancer Journal. 2025; doi:10.1038/s41408-025-01312-x.
  9. Dimopoulos MA, et al. Daratumumab or active monitoring for high-risk smoldering multiple myeloma. New England Journal of Medicine. 2025; doi:10.1056/NEJMoa2409029. Erratum published 2026.
  10. U.S. Food and Drug Administration. FDA approves daratumumab and hyaluronidase-fihj for high-risk smoldering multiple myeloma. Accessed August 4, 2026.

Smoldering multiple myeloma (SMM)